|
|
| (8 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| {{CMG}}
| | #REDIRECT [[Fondaparinux#Contraindications]] |
|
| |
|
| | | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ==Contraindications==
| | [[Category: Anticoagulants]] |
| | |
| '''Fondaparinux sodium''' (Arixtra) Injection is contraindicated in patients with severe [[renal impairment]] ([[creatinine clearance]] <30 mL/min). Fondaparinux sodium (Arixtra) is eliminated primarily by the kidneys, and such patients are at increased risk for major bleeding episodes.
| |
| | |
| Fondaparinux sodium (Arixtra) prophylactic therapy is contraindicated in patients with body weight <50 kg undergoing [[hip fracture]], [[hip replacement]] or [[knee replacement]] surgery, and [[abdominal surgery]]. During the randomized clinical trials of prophylaxis in the peri-operative period following [[hip fracture]], [[hip replacement]], or [[knee replacement]] surgery, occurrence of major bleeding was doubled in patients with a body weight <50 kg compared with those with a body weight ≥50 kg (5.4% versus 2.1%). In the clinical trial in patients undergoing [[abdominal surgery]], the major bleeding rate was also higher in patients with a body weight <50 kg as compared to those with a body weight ≥50 kg (5.3% versus 3.3%), respectively.
| |
| | |
| The use of Fondaparinux sodium (Arixtra) is contraindicated in patients with active major bleeding, [[bacterial endocarditis]], in patients with [[thrombocytopenia]] associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium, or in patients with known hypersensitivity to fondaparinux sodium.
| |
| | |
| | |
| | |
| | |
| {{FDA}}
| |
| | |
| | |
| [[Category:Drugs]] | |